Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral load threshold for pre-emptive CMV therapy in transplant recipients
2007-003472-19Phase 4Terminated
- Sponsor
- Royal Free London NHS Foundation Trust
- Start
- Aug 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ganciclovir, valganciclovir and foscarnet sodium in cytomegalovirus disease (CMV), sponsored by Royal Free London NHS Foundation Trust. Primary endpoint: Number of patients with CMV viral load > 3,000 copies/mL. Started Aug 2007; status: terminated.
02
Drugs
ganciclovirvalganciclovirfoscarnet sodium
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2007-003472-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003472-19.